ORION CORP.B UNSP.ADR 1/2 (OFK0) - Total Liabilities
Based on the latest financial reports, ORION CORP.B UNSP.ADR 1/2 (OFK0) has total liabilities worth €956.70 Million EUR (≈ $1.12 Billion USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore OFK0 net asset momentum to track the company's year-over-year net asset growth rate.
ORION CORP.B UNSP.ADR 1/2 - Total Liabilities Trend (2022–2025)
This chart illustrates how ORION CORP.B UNSP.ADR 1/2's total liabilities have evolved over time, based on quarterly financial data. See ORION CORP.B UNSP.ADR 1/2 free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
ORION CORP.B UNSP.ADR 1/2 Competitors by Total Liabilities
The table below lists competitors of ORION CORP.B UNSP.ADR 1/2 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
AVIC Aircraft Co Ltd
SHE:000768
|
China | CN¥54.73 Billion |
|
NTPC Green Energy Limited
NSE:NTPCGREEN
|
India | Rs295.73 Billion |
|
SPIE SA
PA:SPIE
|
France | €8.12 Billion |
|
SAINSBURY -J.- ADR/4 NEW
F:SUY
|
Germany | €18.00 Billion |
|
OPC Energy Ltd
TA:OPCE
|
Israel | ILA6.98 Billion |
|
GETLINK ADR EO-40
F:TNU
|
Germany | €6.35 Billion |
|
Abivax SA
PA:ABVX
|
France | €129.14 Million |
|
Weichai Power Co. Ltd
F:WI4
|
Germany | €239.03 Billion |
Liability Composition Analysis (2022–2025)
This chart breaks down ORION CORP.B UNSP.ADR 1/2's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market value of ORION CORP.B UNSP.ADR 1/2.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.77 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.85 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.46 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how ORION CORP.B UNSP.ADR 1/2's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for ORION CORP.B UNSP.ADR 1/2 (2022–2025)
The table below shows the annual total liabilities of ORION CORP.B UNSP.ADR 1/2 from 2022 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €725.40 Million ≈ $848.07 Million |
+16.23% |
| 2024-12-31 | €624.10 Million ≈ $729.64 Million |
+13.78% |
| 2023-12-31 | €548.50 Million ≈ $641.25 Million |
-7.89% |
| 2022-12-31 | €595.50 Million ≈ $696.20 Million |
-- |
About ORION CORP.B UNSP.ADR 1/2
Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides pharmaceutical products, which includes Nubeqa for the treatment of prostate cancer; Entacapone, Stalevo, Comtess, and Comtan to treat Parkinson's disease; Burana for inflam… Read more